

Aberrant Expression of Mucin Core Proteins and O-Link Progression of Pancreatic Cancer

Clinical Cancer Research

19, 1981-1993

DOI: [10.1158/1078-0432.ccr-12-2662](https://doi.org/10.1158/1078-0432.ccr-12-2662)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Mucins in pancreatic cancer and its microenvironment. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2013, 10, 607-620.	8.2	232
2	Mechanisms of antitumor and immune-enhancing activities of MUC1/sec, a secreted form of mucin-1. <i>Immunologic Research</i> , 2013, 57, 70-80.	1.3	7
3	Comparison of MUC4 expression in primary pancreatic cancer and paired lymph node metastases. <i>Scandinavian Journal of Gastroenterology</i> , 2013, 48, 1183-1187.	0.6	15
4	Mucins and Cancer. , 2013, , .		2
7	MUC1 Regulates Expression of Multiple microRNAs Involved in Pancreatic Tumor Progression, Including the miR-200c/141 Cluster. <i>PLoS ONE</i> , 2013, 8, e73306.	1.1	32
8	MicroRNA-200c Modulates the Expression of MUC4 and MUC16 by Directly Targeting Their Coding Sequences in Human Pancreatic Cancer. <i>PLoS ONE</i> , 2013, 8, e73356.	1.1	38
9	Ductal adenocarcinoma of the pancreas usually retained SMAD4 and p53 protein status as well as expression of epithelial-to-mesenchymal transition markers and cell cycle regulators at the stage of liver metastasis. <i>Polish Journal of Pathology</i> , 2014, 2, 100-112.	0.1	3
10	High Expression of sLex Associated with Poor Survival in Argentinian Colorectal Cancer Patients. <i>International Journal of Biological Markers</i> , 2014, 29, e30-e39.	0.7	7
11	Inhibition of KL-6/MUC1 glycosylation limits aggressive progression of pancreatic cancer. <i>World Journal of Gastroenterology</i> , 2014, 20, 12171.	1.4	12
12	Loss of E-cadherin and epithelial to mesenchymal transition is not required for cell motility in tissues or for metastasis. <i>Tissue Barriers</i> , 2014, 2, e969112.	1.6	32
13	Immature truncated O-glycophenotype of cancer directly induces oncogenic features. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, E4066-75.	3.3	251
14	MUC1 regulates cyclin D1 gene expression through p120 catenin and β -catenin. <i>Oncogenesis</i> , 2014, 3, e107-e107.	2.1	29
15	Potential applications of nanotechnology for the diagnosis and treatment of pancreatic cancer. <i>Frontiers in Physiology</i> , 2014, 5, 2.	1.3	57
16	Applications of Chemical Ligation in Peptide Synthesis via Acyl Transfer. <i>Topics in Current Chemistry</i> , 2014, 362, 229-265.	4.0	6
17	Interference of Mucin 1 Inhibits Progression of Colon Carcinoma by Repression of Wnt/ β -Catenin Signaling. <i>DNA and Cell Biology</i> , 2014, 33, 162-170.	0.9	8
18	Spatiotemporal Proteomic Analyses during Pancreas Cancer Progression Identifies Serine/Threonine Stress Kinase 4 (STK4) as a Novel Candidate Biomarker for Early Stage Disease. <i>Molecular and Cellular Proteomics</i> , 2014, 13, 3484-3496.	2.5	21
19	Microfluidic immunocapture of circulating pancreatic cells using parallel EpCAM and MUC1 capture: characterization, optimization and downstream analysis. <i>Lab on A Chip</i> , 2014, 14, 1775-1784.	3.1	107
20	Increased expression of <i>GCNT1</i> is associated with altered O-glycosylation of PSA, PAP, and MUC1 in human prostate cancers. <i>Prostate</i> , 2014, 74, 1059-1067.	1.2	52

#	ARTICLE	IF	CITATIONS
21	Specific MUC1 Splice Variants Are Correlated With Tumor Progression in Esophageal Cancer. <i>World Journal of Surgery</i> , 2014, 38, 2052-2057.	0.8	20
22	Recent developments and applications of electron transfer dissociation mass spectrometry in proteomics. <i>Amino Acids</i> , 2014, 46, 1625-1634.	1.2	34
23	Discovery of sialyl Lewis A and Lewis X modified protein cancer biomarkers using high density antibody arrays. <i>Journal of Proteomics</i> , 2014, 96, 291-299.	1.2	55
24	High-Throughput Analysis of Plasma Hybrid Markers for Early Detection of Cancers. <i>Proteomes</i> , 2014, 2, 1-17.	1.7	11
25	The sialyltransferase ST3GAL6 influences homing and survival in multiple myeloma. <i>Blood</i> , 2014, 124, 1765-1776.	0.6	97
26	Colon cancer cells treated with 5-fluorouracil exhibit changes in polylectosamine-type N-glycans. <i>Molecular Medicine Reports</i> , 2014, 9, 1697-1702.	1.1	19
27	A Boronic Acid-Based Enrichment for Site-Specific Identification of the N-glycoproteome Using MS-Based Proteomics. <i>Neuromethods</i> , 2015, , 31-41.	0.2	3
28	Glycomic profiling of carcinoembryonic antigen isolated from human tumor tissue. <i>Clinical Proteomics</i> , 2015, 12, 17.	1.1	24
29	The O-Linked Glycome and Blood Group Antigens ABO on Mucin-Type Glycoproteins in Mucinous and Serous Epithelial Ovarian Tumors. <i>PLoS ONE</i> , 2015, 10, e0130197.	1.1	27
30	Glycosyltransferases involved in the synthesis of MUC-associated metastasis-promoting selectin ligands. <i>Glycobiology</i> , 2015, 25, 963-975.	1.3	12
31	Synthesis and cell-selective antitumor properties of amino acid conjugated tumor-associated carbohydrate antigen-coated gold nanoparticles. <i>Carbohydrate Research</i> , 2015, 405, 93-101.	1.1	30
32	Cyst Fluid Biomarkers for Intraductal Papillary Mucinous Neoplasms of the Pancreas: A Critical Review from the International Expert Meeting on Pancreatic Branch-Duct-Intraductal Papillary Mucinous Neoplasms. <i>Journal of the American College of Surgeons</i> , 2015, 220, 243-253.	0.2	64
33	The intestinal glycome and its modulation by diet and nutrition. <i>Nutrition Reviews</i> , 2015, 73, 359-375.	2.6	30
34	Total synthesis of LewisX using a late-stage crystalline intermediate. <i>Carbohydrate Research</i> , 2015, 414, 1-7.	1.1	6
35	The cancer glycome: Carbohydrates as mediators of metastasis. <i>Blood Reviews</i> , 2015, 29, 269-279.	2.8	91
36	Protein Ligation and Total Synthesis I. <i>Topics in Current Chemistry</i> , 2015, , .	4.0	2
37	Upregulation of Glycans Containing 3- α -Fucose in a Subset of Pancreatic Cancers Uncovered Using Fusion-Tagged Lectins. <i>Journal of Proteome Research</i> , 2015, 14, 2594-2605.	1.8	24
38	Integrated proteo-genomic approach for early diagnosis and prognosis of cancer. <i>Cancer Letters</i> , 2015, 369, 28-36.	3.2	30

#	ARTICLE	IF	CITATIONS
39	Lectin Microarray-Based Sero-Biomarker Verification Targeting Aberrant α -Linked Glycosylation on Mucin 1. <i>Analytical Chemistry</i> , 2015, 87, 7274-7281.	3.2	46
40	Mucins: A biologically relevant glycan barrier in mucosal protection. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2015, 1850, 236-252.	1.1	389
42	Overexpression of ST3Gal-I promotes migration and invasion of HCCLM3 in vitro and poor prognosis in human hepatocellular carcinoma. <i>OncoTargets and Therapy</i> , 2016, 9, 2227.	1.0	20
43	Glycomic Approaches for the Discovery of Targets in Gastrointestinal Cancer. <i>Frontiers in Oncology</i> , 2016, 6, 55.	1.3	47
44	MUC1 Vaccines, Comprised of Glycosylated or Non-Glycosylated Peptides or Tumor-Derived MUC1, Can Circumvent Immunoediting to Control Tumor Growth in MUC1 Transgenic Mice. <i>PLoS ONE</i> , 2016, 11, e0145920.	1.1	31
45	Functional Consequences of Differential O-glycosylation of MUC1, MUC4, and MUC16 (Downstream) Tj ETQq1 1 0,784314 rgBT /Over	1.8	58
46	Acquired resistance to HSP90 inhibitor 17-AAG and increased metastatic potential are associated with MUC1 expression in colon carcinoma cells. <i>Anti-Cancer Drugs</i> , 2016, 27, 417-426.	0.7	7
47	Semiquantitative immunohistochemistry for mucin (MUC1, MUC2, MUC3, MUC4, MUC5AC, and MUC6) profiling of pancreatic ductal cell adenocarcinoma improves diagnostic and prognostic performance. <i>Histopathology</i> , 2016, 69, 582-591.	1.6	30
48	Morphological Changes, Cadherin Switching, and Growth Suppression in Pancreatic Cancer by GALNT6 Knockdown. <i>Neoplasia</i> , 2016, 18, 265-272.	2.3	27
49	Up-regulation of N-cadherin by Collagen I-activated Discoidin Domain Receptor 1 in Pancreatic Cancer Requires the Adaptor Molecule Shc1. <i>Journal of Biological Chemistry</i> , 2016, 291, 23208-23223.	1.6	53
50	Stromal ETS2 Regulates Chemokine Production and Immune Cell Recruitment during Acinar-to-Ductal Metaplasia. <i>Neoplasia</i> , 2016, 18, 541-552.	2.3	25
51	Distal bile duct carcinomas and pancreatic ductal adenocarcinomas: postulating a common tumor entity. <i>Cancer Medicine</i> , 2016, 5, 88-99.	1.3	45
52	Predictive imaging of chemotherapeutic response in a transgenic mouse model of pancreatic cancer. <i>International Journal of Cancer</i> , 2016, 139, 712-718.	2.3	12
53	Reflections on MUC1 glycoprotein: the hidden potential of isoforms in carcinogenesis. <i>Apmis</i> , 2016, 124, 913-924.	0.9	17
54	Genetic ablation of Smoothed in pancreatic fibroblasts increases acinar \rightarrow ductal metaplasia. <i>Genes and Development</i> , 2016, 30, 1943-1955.	2.7	46
55	Proteomic strategies in the search for novel pancreatic cancer biomarkers and drug targets: recent advances and clinical impact. <i>Expert Review of Proteomics</i> , 2016, 13, 383-394.	1.3	7
56	Prospects for adoptive immunotherapy of pancreatic cancer using chimeric antigen receptor-engineered T-cells. <i>Immunopharmacology and Immunotoxicology</i> , 2016, 38, 50-60.	1.1	8
57	Low MUC4 expression is associated with survival benefit in patients with resectable pancreatic cancer receiving adjuvant gemcitabine. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 595-600.	0.6	12

#	ARTICLE	IF	CITATIONS
58	The Synthesis and Biological Characterization of Acetal-Free Mimics of the Tumor-Associated Carbohydrate Antigens. <i>Advances in Carbohydrate Chemistry and Biochemistry</i> , 2017, 74, 137-237.	0.4	6
59	Toll like receptors TLR1/2, TLR6 and MUC5B as binding interaction partners with cytostatic proline rich polypeptide 1 in human chondrosarcoma. <i>International Journal of Oncology</i> , 2018, 52, 139-154.	1.4	10
60	Identification and Validation of Novel Subtype-Specific Protein Biomarkers in Pancreatic Ductal Adenocarcinoma. <i>Pancreas</i> , 2017, 46, 311-322.	0.5	22
61	Probing mucin interaction behavior of magnetic nanoparticles. <i>Journal of Colloid and Interface Science</i> , 2017, 488, 258-268.	5.0	30
62	Nutrients and the Pancreas: An Epigenetic Perspective. <i>Nutrients</i> , 2017, 9, 283.	1.7	23
63	Tn and STn are members of a family of carbohydrate tumor antigens that possess carbohydrate-carbohydrate interactions. <i>Glycobiology</i> , 2018, 28, 437-442.	1.3	16
64	Analysis of sialyl-Lewis x on MUC5AC and MUC1 mucins in pancreatic cancer tissues. <i>International Journal of Biological Macromolecules</i> , 2018, 112, 33-45.	3.6	18
65	The Glycoproteomics-MS for Studying Glycosylation in Cardiac Hypertrophy and Heart Failure. <i>Proteomics - Clinical Applications</i> , 2018, 12, e1700075.	0.8	17
66	Glycan-directed CAR-T cells. <i>Glycobiology</i> , 2018, 28, 656-669.	1.3	74
67	Can we better predict the biologic behavior of incidental IPMN? A comprehensive analysis of molecular diagnostics and biomarkers in intraductal papillary mucinous neoplasms of the pancreas. <i>Langenbeck's Archives of Surgery</i> , 2018, 403, 151-194.	0.8	18
68	Emerging Therapeutic Targets in Pancreatic Adenocarcinoma. , 2018, , 1613-1641.		2
69	Detecting the Sweet Biomarker on Cancer Cells. <i>ACS Central Science</i> , 2018, 4, 428-430.	5.3	3
70	Cancer glycan epitopes: biosynthesis, structure and function. <i>Glycobiology</i> , 2018, 28, 670-696.	1.3	55
71	Lewis x Antigen is Associated to Head and Neck Squamous Cell Carcinoma Survival. <i>Pathology and Oncology Research</i> , 2018, 24, 525-531.	0.9	6
72	Oxygen by Carbon Replacement at the Glycosidic Linkage Modulates the Sugar Conformation in Tn Antigen Mimics. <i>ACS Omega</i> , 2018, 3, 18142-18152.	1.6	5
73	MUC16 mutations improve patients' prognosis by enhancing the infiltration and antitumor immunity of cytotoxic T lymphocytes in the endometrial cancer microenvironment. <i>Oncolmmunology</i> , 2018, 7, e1487914.	2.1	27
74	Disruption of C1galt1 Gene Promotes Development and Metastasis of Pancreatic Adenocarcinomas in Mice. <i>Gastroenterology</i> , 2018, 155, 1608-1624.	0.6	59
75	Bioengineered cellular and cell membrane-derived vehicles for actively targeted drug delivery: So near and yet so far. <i>Advanced Drug Delivery Reviews</i> , 2018, 132, 57-80.	6.6	99

#	ARTICLE	IF	CITATIONS
76	Toward Automated Enzymatic Synthesis of Oligosaccharides. <i>Chemical Reviews</i> , 2018, 118, 8151-8187.	23.0	153
77	Mucin-1 is required for Coxsackie Virus B3-induced inflammation in pancreatitis. <i>Scientific Reports</i> , 2019, 9, 10656.	1.6	2
78	Nerves and Pancreatic Cancer: New Insights into a Dangerous Relationship. <i>Cancers</i> , 2019, 11, 893.	1.7	50
79	GALNT6 Promotes Tumorigenicity and Metastasis of Breast Cancer Cell via β -catenin/MUC1-C Signaling Pathway. <i>International Journal of Biological Sciences</i> , 2019, 15, 169-182.	2.6	20
80	I-branched carbohydrates as emerging effectors of malignant progression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 13729-13737.	3.3	28
81	Construction of lanthanide-doped upconversion nanoparticle-Ulex Europaeus Agglutinin-I bioconjugates with brightness red emission for ultrasensitive in vivo imaging of colorectal tumor. <i>Biomaterials</i> , 2019, 212, 64-72.	5.7	46
82	The glycosylation landscape of pancreatic cancer (Review). <i>Oncology Letters</i> , 2019, 17, 2569-2575.	0.8	70
83	Diagnostic Significance of Serum IgG Galactosylation in CA19-9-Negative Pancreatic Carcinoma Patients. <i>Frontiers in Oncology</i> , 2019, 9, 114.	1.3	12
84	Functional Expression of Mucin1 in Human Duodenal Adenocarcinoma. <i>Journal of Surgical Research</i> , 2019, 238, 79-89.	0.8	6
85	Single molecule characterization of individual extracellular vesicles from pancreatic cancer. <i>Journal of Extracellular Vesicles</i> , 2019, 8, 1685634.	5.5	60
86	Circulating natural antibodies against 3â€™-sialyllactose complement the diagnostic performance of CA19-9 for the early detection of pancreatic ductal adenocarcinoma. <i>Cancer Biomarkers</i> , 2019, 27, 121-128.	0.8	3
87	Assessing the prognostic significance of MUC4 β in mucoepidermoid carcinoma of the salivary glands: An immunohistochemical study. <i>Heliyon</i> , 2019, 5, e02753.	1.4	3
88	Proteome alterations in pancreatic ductal adenocarcinoma. <i>Cancer Letters</i> , 2020, 469, 429-436.	3.2	30
89	LAMTOR5 raises abnormal initiation of O-glycosylation in breast cancer metastasis via modulating GALNT1 activity. <i>Oncogene</i> , 2020, 39, 2290-2304.	2.6	26
90	Metastasis in Pancreatic Ductal Adenocarcinoma: Current Standing and Methodologies. <i>Genes</i> , 2020, 11, 6.	1.0	31
91	Tumor-associated carbohydrates and immunomodulatory lectins as targets for cancer immunotherapy. , 2020, 8, e001222.		60
92	Comparative Animal Mucomics: Inspiration for Functional Materials from Ubiquitous and Understudied Biopolymers. <i>ACS Biomaterials Science and Engineering</i> , 2020, 6, 5377-5398.	2.6	12
93	A Systematic Review on the Implications of O-linked Glycan Branching and Truncating Enzymes on Cancer Progression and Metastasis. <i>Cells</i> , 2020, 9, 446.	1.8	52

#	ARTICLE	IF	CITATIONS
94	In vivo anti-MUC1+ tumor activity and sequences of high-affinity anti-MUC1-SEA antibodies. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1337-1352.	2.0	15
95	Ser and Thr acceptor preferences of the GalNAc-Ts vary among isoenzymes to modulate mucin-type O-glycosylation. <i>Glycobiology</i> , 2020, 30, 910-922.	1.3	25
96	Polyanhydride nanoparticles stabilize pancreatic cancer antigen <scp>MUC4 ² </scp>. <i>Journal of Biomedical Materials Research - Part A</i> , 2021, 109, 893-902.	2.1	29
97	Glycan Biomarkers in Pancreatic Cancer. , 2021, , 471-482.		0
98	Sialic Acids and Their Influence on Human NK Cell Function. <i>Cells</i> , 2021, 10, 263.	1.8	14
99	Integrated proteomics and phosphoproteomics reveal perturbed regulative pathways in pancreatic ductal adenocarcinoma. <i>Molecular Omics</i> , 2021, 17, 230-240.	1.4	5
100	Isoforms of MUC16 activate oncogenic signaling through EGF receptors to enhance the progression of pancreatic cancer. <i>Molecular Therapy</i> , 2021, 29, 1557-1571.	3.7	25
101	MUC4 enhances gemcitabine resistance and malignant behaviour in pancreatic cancer cells expressing cancer-associated short O-glycans. <i>Cancer Letters</i> , 2021, 503, 91-102.	3.2	24
102	Abnormal Glycosylation of Cancer Stem Cells and Targeting Strategies. <i>Frontiers in Oncology</i> , 2021, 11, 649338.	1.3	17
103	Glycoproteomic bioanalysis of exosomes by LC-MS for early diagnosis of pancreatic cancer. <i>Bioanalysis</i> , 2021, 13, 861-864.	0.6	10
104	Display of the human mucinome with defined O-glycans by gene engineered cells. <i>Nature Communications</i> , 2021, 12, 4070.	5.8	67
105	Apical Membrane Expression of Distinct Sulfated Glycans Is a Characteristic Feature of Ductules and Their Reactive and Neoplastic Counterparts. <i>Journal of Histochemistry and Cytochemistry</i> , 2021, 69, 555-573.	1.3	6
106	A glycosyltransferase gene signature to detect pancreatic ductal adenocarcinoma patients with poor prognosis. <i>EBioMedicine</i> , 2021, 71, 103541.	2.7	22
107	Mapping of truncated O-glycans in cancers of epithelial and non-epithelial origin. <i>British Journal of Cancer</i> , 2021, 125, 1239-1250.	2.9	29
108	Glycans in stem cell regulation: from <i>Drosophila</i> tissue stem cells to mammalian pluripotent stem cells. <i>FEBS Letters</i> , 2018, 592, 3773-3790.	1.3	24
109	Assessment of tumor characteristics based on glycoform analysis of membrane-tethered MUC1. <i>Laboratory Investigation</i> , 2017, 97, 1103-1113.	1.7	20
110	O-glycan recognition and function in mice and human cancers. <i>Biochemical Journal</i> , 2020, 477, 1541-1564.	1.7	47
111	Verteporfin- and sodium porfimer-mediated photodynamic therapy enhances pancreatic cancer cell death without activating stromal cells in the microenvironment. <i>Journal of Biomedical Optics</i> , 2019, 24, 1.	1.4	22

#	ARTICLE	IF	CITATIONS
112	C1GALT1 Promotes Invasive Phenotypes of Hepatocellular Carcinoma Cells by Modulating Integrin α 21 Glycosylation and Activity. PLoS ONE, 2014, 9, e94995.	1.1	37
113	Glycan-specific antibodies as potential cancer biomarkers: a focus on microarray applications. Clinical Chemistry and Laboratory Medicine, 2020, 58, 1611-1622.	1.4	15
114	Identification of PAM4 (clivatuzumab)-reactive epitope on MUC5AC: A promising biomarker and therapeutic target for pancreatic cancer. Oncotarget, 2015, 6, 4274-4285.	0.8	19
115	Targeting cancer cell metabolism in pancreatic adenocarcinoma. Oncotarget, 2015, 6, 16832-16847.	0.8	100
116	Active YAP promotes pancreatic cancer cell motility, invasion and tumorigenesis in a mitotic phosphorylation-dependent manner through LPAR3. Oncotarget, 2015, 6, 36019-36031.	0.8	86
117	Tumor necrosis factor- α and interferon- γ stimulate MUC16 (CA125) expression in breast, endometrial and ovarian cancers through NF- κ B. Oncotarget, 2016, 7, 14871-14884.	0.8	44
118	Glycoproteins and glycoproteomics in pancreatic cancer. World Journal of Gastroenterology, 2016, 22, 9288.	1.4	59
119	Glycoprotein biomarkers for the detection of pancreatic ductal adenocarcinoma. World Journal of Gastroenterology, 2018, 24, 2537-2554.	1.4	30
120	Reduction in O-glycome induces differentially glycosylated CD44 to promote stemness and metastasis in pancreatic cancer. Oncogene, 2022, 41, 57-71.	2.6	15
121	Mucin Expression and Splicing Determine Novel Subtypes and Patient Mortality in Pancreatic Ductal Adenocarcinoma. Clinical Cancer Research, 2021, 27, 6787-6799.	3.2	9
122	Emerging Therapeutic Targets in Pancreatic Adenocarcinoma. , 2016, , 1-29.		1
123	Mixed- α Sugars: Glycosyltransferase Cross-Reactivity in Cancerous Tissues and Their Therapeutic Targeting. ChemBioChem, 2022, 23, .	1.3	2
124	Presentation of underglycosylated mucin 1 in pancreatic adenocarcinoma (PDAC) at early stages. American Journal of Cancer Research, 2016, 6, 1986-1995.	1.4	4
125	The next "sweet" spot for pancreatic ductal adenocarcinoma: Glycoprotein for early detection. Mass Spectrometry Reviews, 2023, 42, 822-843.	2.8	10
126	Organoids at the PUB: The Porcine Urinary Bladder Serves as a Pancreatic Niche for Advanced Cancer Modeling. Advanced Healthcare Materials, 2022, 11, e2102345.	3.9	7
127	Gasdermin E mediates resistance of pancreatic adenocarcinoma to enzymatic digestion through a YBX1- α mucin pathway. Nature Cell Biology, 2022, 24, 364-372.	4.6	19
128	An Introduction to the Relationship Between Lewis x and Malignancy Mainly Related to Breast Cancer and Head Neck Squamous Cell Carcinoma (HNSCC). Cancer Investigation, 2022, 40, 173-183.	0.6	4
130	Altered glycosylation in pancreatic cancer and beyond. Journal of Experimental Medicine, 2022, 219, .	4.2	27

#	ARTICLE	IF	CITATIONS
131	Truncated O-Glycan-Bearing MUC16 Enhances Pancreatic Cancer Cells Aggressiveness via $\alpha 4 \beta 1$ Integrin Complexes and FAK Signaling. International Journal of Molecular Sciences, 2022, 23, 5459.	1.8	8
132	Role of tumor cell sialylation in pancreatic cancer progression. Advances in Cancer Research, 2023, , 123-155.	1.9	6
133	Combination of Changes in CEA and CA199 Concentration After Neoadjuvant Chemoradiotherapy Could Predict the Prognosis of Stage II/III Rectal Cancer Patients Receiving Neoadjuvant Chemoradiotherapy Followed by Total Mesorectal Excision. Cancer Management and Research, 0, Volume 14, 2933-2944.	0.9	1
134	Abnormal Glycosylation in Cancer Cells and Cancer Stem Cells as a Therapeutic Target. Advances in Experimental Medicine and Biology, 2022, , 141-156.	0.8	0
137	Pancreatic Cancer: Pursuit of Mucins from Progression to Prognosis. , 2023, , 1-19.		0